Zeltia : GENOMICA and the Foundation for Excellence and Quality in Oncology announce a framework agreement for collaboration in Oncology

ZELTIA INFORMA:

GENOMICA and the Foundation for Excellence and Quality in Oncology announce a framework agreement for collaboration in Oncology

The partnership will seek to improve quality cancer care in Spain by encouraging research projects, optimized use of GENOMICA diagnostic kits, scientific and medical dissemination and training of oncology professionals

Madrid, July 22, 2015 - GENOMICA, a Spanish leading molecular diagnostics company, has entered a broad collaboration agreement with the Foundation for Excellence andQuality in Oncologyfocused on improving cancer care by fostering research projects and clinical management across different disciplines in oncology.
This important agreement is the first one carried out by a Spanish biotechnology company and the prestigious Spanish Foundation. The goals of this collaboration is to strengthen the mission of GENOMICA to facilitate reliable and optimized molecular diagnostics tools in clinic practice and to be aligned with the basis of the ECO Foundation for boosting advances in Spanish oncology. This will offer patients the best resources.
Among the different activities that will be performed under this agreement, GENOMICA and the ECO Foundation will promote training courses and conferences, forums for scientific dissemination, health-focused research projects, publication of scientific articles as well as events geared to the general audience.
"We are proud to begin this collaboration with the ECO Foundation, which will be key to start other important diagnosis-centered projects with oncologists all over Spain." said Rosario Cospedal, Managing Director at GENOMICA. "We are looking forward to providing oncologists and cancer researchers with our expertise in molecular diagnostics to carry out different initiatives from this agreement."
The President of the ECO Foundation, Dr. Vicente Guillem, was very pleased with the agreement, which will allow intensifying the work of the organization in the field of genetic analysis and precision medicine in oncology. The ECO Foundation has conducted several scientific initiatives in this line, which are considered key for the future of cancer treatment. To promote guidelines that will improve the quality of Spanish Oncology in all its aspects, " this agreement will open new forums for debate and analysis that will allow us to advance
in the new era of personalized medicine", said the renowned oncologist, Dr. Guillem .
1

Image: Vicente Guillem, MD. President of ECO Foundation; and Rosario Cospedal, GENOMICA Managing Director.

About GENOMICA

GENOMICA S.A.U. is Spain's leading molecular diagnostics company. Founded in 1990, the company is based in Madrid and it is wholly owned by the holding company Zeltia (ZEL). The company's mission is improve the current approach to molecular diagnostics in the life sciences by providing reliable and automated diagnostic tools. GENOMICA S.A.U. is aiming to lead the Spanish market and to expand internationally in the area of molecular diagnostics and personalized medicine by designing, developing and selling new genomic applications based on the CLART® (CLINICAL ARRAY TECHNOLOGY)platform. GENOMICA has developed diagnostic tests for various infectious diseases and tumor types and markets a test for detecting genetic markers associated with response to therapy. GENOMICA is also a leading supplier of genetic identification services in legal and forensic medicine and in technology transfer (turnkey laboratories). Please visit us at
http://www.genomica.es/

About Foundation for Excellence and Quality in Oncology

2

ECO Foundation is a platform of experts composed of heads of medical oncology departments from leading hospitals in Spain. It aims to achieve excellence and quality in oncology by seeking and developing solutions and tools that can promote quality in three areas: patient care, specialized training and promotion of research.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Inquiries:

Carolina Pola - Communications Director
Mobile: [phone]
Phone: [phone]
Or please visit our website at http://www.genomica.es
3